Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS - Full Text View

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00118378

Purpose

This study will determine whether modafinil (Provigil®), a medication approved for the treatment of narcolepsy, is effective in reducing fatigue in adults with HIV/AIDS.

Condition	Intervention	Phase
HIV Infections Fatigue	Drug: Modafinil	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Modafinil Treatment for Fatigue in HIV+ Patients

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Depression Fatigue HIV/AIDS

Drug Information available for: Modafinil

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:

Fatigue severity scale outcome [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: No ]
Role function scale outcome [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

CD4 cell count [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: Yes ]
HIV viral load [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: Yes ]
Hamilton Rating Scale for Depression [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: No ]
Beck Depression Inventory II [ Time Frame: Measured at baseline and Weeks 4 and 12 ] [ Designated as safety issue: No ]
Cognitive function [ Time Frame: Measured at baseline and Week 4 ] [ Designated as safety issue: No ]

Enrollment:	115
Study Start Date:	January 2005
Study Completion Date:	November 2010
Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1. Modafinil, responsive Participants will take modafinil for 4 weeks. If responsive, participants will be offered 8 additional weeks of modafinil.	Drug: Modafinil 50 mg per day, increasing to 200 mg per day as clinically indicated Other Name: Provigil
Placebo Comparator: 2. Placebo, Modafinil Participants will take placebo for 4 weeks, then a 12-week course of modafinil.	Drug: Modafinil 50 mg per day, increasing to 200 mg per day as clinically indicated Other Name: Provigil
Experimental: 3. Modafinil, nonresponsive Participants will take modafinil for 4 weeks. If nonresponsive, they will be offered an alternative treatment.	Drug: Modafinil 50 mg per day, increasing to 200 mg per day as clinically indicated Other Name: Provigil

Detailed Description:

Fatigue is a common problem for many people with HIV/AIDS, interfering with daily activities and serving as a significant barrier to working among those whose health is otherwise stable or restored by antiretroviral (ARV) medication. Fatigue in HIV is associated with disability and diminished quality of life. It may be caused by ARVs or by the virus itself. This study will determine if modafinil can reduce fatigue in HIV/AIDS patients.

This study will last 12 weeks. Participants will be randomly assigned to receive either modafinil or placebo daily for 4 weeks. Participants who show an improvement in symptoms will receive modafinil for an additional 8 weeks. Participants who do not respond to modafinil will have the opportunity to receive other drug treatments. All participants will have weekly study visits for the first 4 weeks of the study and biweekly visits for the remainder of the study. At each visit, participants will complete various tasks to determine cognitive function and self-report scales will be used to determine symptoms of depression and fatigue.

For information on an identical study using a related drug, please follow this URL: http://clinicaltrials.gov/show/NCT00737204

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV infected
Clinically significant fatigue for at least 3 months before study entry
Able to speak English
Willing to use acceptable methods of contraception

Exclusion Criteria:

Insufficient production of thyroid hormones (hypothyroidism) or untreated malfunctioning of testes or ovaries (hypogonadism)
Uncontrolled hypertension
Clinically significant anemia
Initiation of testosterone or nandrolone (a steroid) treatment within 6 weeks before study entry
Began or changed an ARV regimen within 12 weeks before study entry
Untreated major depression
Initiation of antidepressant medication within 6 weeks before study entry
Current substance abuse or dependence that may interfere with the study
Regular cannabis use
Previous or current nondrug-induced psychosis or bipolar disorder
Current use of psychostimulant medication
Previous nonresponse to an adequate trial of modafinil
Any unstable medical condition
Previously failed ARV regimens and currently on last viable ARV regimen
Pregnancy or breastfeeding
Primary care doctor does not approve of study participation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00118378

Locations

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

Principal Investigator:

Judith G. Rabkin, PhD, MPH

Columbia University

More Information

Additional Information:

Click here for a related study currently recruiting participants. This link exits the ClinicalTrials.gov site

Publications:

Rabkin JG, McElhiney M, Rabkin R, McGrath P. Modafinil treatment for fatigue in HIV/AIDS: A randomized placebo-ctontrolled study. J. Clinical Psychiatry 2010; 71:707-715

Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry. 2004 Dec;65(12):1688-95.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry. 2010 Jun;71(6):707-15. Epub 2010 May 4.

Responsible Party:	Judith Rabkin, PhD, New York State Psychiatric Institute
ClinicalTrials.gov Identifier:	NCT00118378 History of Changes
Other Study ID Numbers:	R01 MH072383-01, DAHBR 9A-ASNM
Study First Received:	July 6, 2005
Last Updated:	November 23, 2010
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

HIV
AIDS
Modafinil
Depression

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Fatigue
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

Slow Virus Diseases
Signs and Symptoms
Modafinil
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Neuroprotective Agents
Protective Agents

ClinicalTrials.gov processed this record on February 12, 2012